

SMALL CELL

SCRX001-004: A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients with Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer

<https://clinicaltrials.gov/ct2/show/NCT02819999?term=SCRX001-004&rank=1>

M16-300: A Phase 1/2 Study on the Safety of Rovalpituzumab Tesirine Administered in Combination with Nivolumab or Nivolumab and Ipilimumab for Adults with Extensive-Stage Small Cell Lung Cancer

<https://clinicaltrials.gov/ct2/show/NCT03026166?term=M16-300&rank=1>

NON-SMALL CELL

CA209-816: A Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CheckMate 816: CHECKpoint pathway and nivolumab Clinical Trial Evaluation 816)

<https://clinicaltrials.gov/ct2/show/NCT02998528?term=CA209-816&rank=1>

GO29527: A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared with Best Supportive Care Following Adjuvant Cisplatin Based Chemotherapy in PD L1-Selected Patients with Completely Resected Stage IB-III A Non-Small Cell Lung Cancer.

<https://clinicaltrials.gov/ct2/show/NCT02486718?term=GO29527&rank=1>

A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST). Genetic Testing in screening patients with Stage IB-III A Non-Small Cell Lung Cancer That has been or will be removed by surgery.

<https://clinicaltrials.gov/ct2/show/NCT02194738?term=A151216&rank=1>



A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC).

<https://clinicaltrials.gov/ct2/show/NCT02193282?term=A081105&rank=2>

E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein.

<https://clinicaltrials.gov/ct2/show/NCT02201992?term=E4512&rank=1>

1st LINE ADVANCED AND OR RECURRENT NSCL

14X-MC-JFCP: A Single-Arm, Multicenter, Open-Label, Phase 2 Study of nab®-Paclitaxel (Abraxane®) and Carboplatin Chemotherapy plus Necitumumab (LY3012211)(mAb) in the First-Line Treatment of Patients with Stage IV Squamous Non-Small Cell Lung Cancer

MK3475 PN 407: A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)

<https://clinicaltrials.gov/ct2/show/NCT02775435?term=Keynote+407&rank=1>

1st LINE ADVANCED AND OR RECURRENT NSCL

ML39237 BFIRST: A Phase II Single-Arm Study of Atezolizumab Monotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Clinical Evaluation of Novel Blood-Based Diagnostics

<https://clinicaltrials.gov/ct2/show/NCT02848651?term=ML39237&rank=1>

2nd LINE ADVANCED OR RECURRENT NSCL



54767414LUC2001: A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer

<https://clinicaltrials.gov/ct2/show/NCT03023423?term=54767414LUC2001&rank=1>

